瑞典患者登记中对COVID-19疫苗潜在不良反应的心肌炎诊断的验证

IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Upsala journal of medical sciences Pub Date : 2023-01-01 DOI:10.48101/ujms.v128.9290
Rolf Gedeborg, Lennart Holm, Nils Feltelius, Anders Sundström, Kai M Eggers, Marja-Leena Nurminen, Maria Grünewald, Nicklas Pihlström, Björn Zethelius, Rickard Ljung
{"title":"瑞典患者登记中对COVID-19疫苗潜在不良反应的心肌炎诊断的验证","authors":"Rolf Gedeborg,&nbsp;Lennart Holm,&nbsp;Nils Feltelius,&nbsp;Anders Sundström,&nbsp;Kai M Eggers,&nbsp;Marja-Leena Nurminen,&nbsp;Maria Grünewald,&nbsp;Nicklas Pihlström,&nbsp;Björn Zethelius,&nbsp;Rickard Ljung","doi":"10.48101/ujms.v128.9290","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain.</p><p><strong>Methods: </strong>Patient records for subjects < 40 years of age and a diagnosis of myocarditis in the Swedish National Patient Register were manually reviewed. Brighton Collaboration diagnosis criteria for myocarditis were applied based on patient history, clinical examination, laboratory data, electrocardiograms, echocardiography, magnetic resonance imaging and myocardial biopsy. Poisson regression was used to estimate incidence rate ratios, comparing the register-based outcome variable to validated outcomes. Interrater reliability was assessed by a blinded re-evaluation.</p><p><strong>Results: </strong>Overall, 95.6% (327/342) of cases registered as myocarditis were confirmed (definite, probable or possible myocarditis according to Brighton Collaboration diagnosis criteria, positive predictive value 0.96 [95% CI 0.93-0.98]). Of the 4.4% (15/342) cases reclassified as no myocarditis or as insufficient information, two cases had been exposed to the COVID-19 vaccine no more than 28 days before the myocarditis diagnosis, two cases were exposed >28 days before admission and 11 cases were unexposed to the vaccine. The reclassification had only minor impact on incidence rate ratios for myocarditis following COVID-19 vaccination. In total, 51 cases were sampled for a blinded re-evaluation. Of the 30 randomly sampled cases initially classified as either definite or probably myocarditis, none were re-classified after re-evaluation. Of the in all 15 cases initially classified as no myocarditis or insufficient information, 7 were after re-evaluation re-classified as probable or possible myocarditis. This re-classification was mostly due to substantial variability in electrocardiogram interpretation.</p><p><strong>Conclusion: </strong>This validation of register-based diagnoses of myocarditis by manual patient record review confirmed the register diagnosis in 96% of cases and had high interrater reliability. Reclassification had only a minor impact on the incidence rate ratios for myocarditis following COVID-19 vaccination.</p>","PeriodicalId":23458,"journal":{"name":"Upsala journal of medical sciences","volume":"128 ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202079/pdf/","citationCount":"0","resultStr":"{\"title\":\"Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines.\",\"authors\":\"Rolf Gedeborg,&nbsp;Lennart Holm,&nbsp;Nils Feltelius,&nbsp;Anders Sundström,&nbsp;Kai M Eggers,&nbsp;Marja-Leena Nurminen,&nbsp;Maria Grünewald,&nbsp;Nicklas Pihlström,&nbsp;Björn Zethelius,&nbsp;Rickard Ljung\",\"doi\":\"10.48101/ujms.v128.9290\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain.</p><p><strong>Methods: </strong>Patient records for subjects < 40 years of age and a diagnosis of myocarditis in the Swedish National Patient Register were manually reviewed. Brighton Collaboration diagnosis criteria for myocarditis were applied based on patient history, clinical examination, laboratory data, electrocardiograms, echocardiography, magnetic resonance imaging and myocardial biopsy. Poisson regression was used to estimate incidence rate ratios, comparing the register-based outcome variable to validated outcomes. Interrater reliability was assessed by a blinded re-evaluation.</p><p><strong>Results: </strong>Overall, 95.6% (327/342) of cases registered as myocarditis were confirmed (definite, probable or possible myocarditis according to Brighton Collaboration diagnosis criteria, positive predictive value 0.96 [95% CI 0.93-0.98]). Of the 4.4% (15/342) cases reclassified as no myocarditis or as insufficient information, two cases had been exposed to the COVID-19 vaccine no more than 28 days before the myocarditis diagnosis, two cases were exposed >28 days before admission and 11 cases were unexposed to the vaccine. The reclassification had only minor impact on incidence rate ratios for myocarditis following COVID-19 vaccination. In total, 51 cases were sampled for a blinded re-evaluation. Of the 30 randomly sampled cases initially classified as either definite or probably myocarditis, none were re-classified after re-evaluation. Of the in all 15 cases initially classified as no myocarditis or insufficient information, 7 were after re-evaluation re-classified as probable or possible myocarditis. This re-classification was mostly due to substantial variability in electrocardiogram interpretation.</p><p><strong>Conclusion: </strong>This validation of register-based diagnoses of myocarditis by manual patient record review confirmed the register diagnosis in 96% of cases and had high interrater reliability. Reclassification had only a minor impact on the incidence rate ratios for myocarditis following COVID-19 vaccination.</p>\",\"PeriodicalId\":23458,\"journal\":{\"name\":\"Upsala journal of medical sciences\",\"volume\":\"128 \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202079/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Upsala journal of medical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.48101/ujms.v128.9290\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Upsala journal of medical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.48101/ujms.v128.9290","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:以出院诊断为结果,冠状病毒病2019 (COVID-19) mRNA疫苗与心肌炎风险增加相关。这些基于挂号的诊断的有效性是不确定的。方法:人工查阅瑞典国家患者登记册中年龄< 40岁的患者记录和心肌炎诊断。根据患者病史、临床检查、实验室资料、心电图、超声心动图、磁共振成像和心肌活检,应用布莱顿协作诊断标准诊断心肌炎。泊松回归用于估计发病率比,比较基于登记的结果变量和验证的结果。通过盲法再评价评估间信度。结果:总体上,95.6%(327/342)的心肌炎病例被确诊(根据Brighton Collaboration诊断标准确诊、可能或可能的心肌炎,阳性预测值0.96 [95% CI 0.93-0.98])。在无心肌炎或信息不充分的4.4%(15/342)病例中,2例在心肌炎诊断前接触新冠肺炎疫苗不超过28天,2例在入院前接触新冠肺炎疫苗>28天,11例未接触新冠肺炎疫苗。重新分类对COVID-19疫苗接种后心肌炎发病率的影响较小。总共有51例病例被抽样进行盲法重新评估。在30例随机抽样的最初确诊或可能为心肌炎的病例中,没有一例在重新评估后被重新确诊。在15例最初未诊断为心肌炎或信息不充分的病例中,7例经重新评估后重新诊断为可能或可能的心肌炎。这种重新分类主要是由于心电图解释的实质性变化。结论:通过手工病历复习对心肌炎的登记诊断进行了验证,96%的病例的登记诊断得到了证实,且具有较高的互信度。重新分类仅对COVID-19疫苗接种后心肌炎的发生率有轻微影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines.

Background: Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain.

Methods: Patient records for subjects < 40 years of age and a diagnosis of myocarditis in the Swedish National Patient Register were manually reviewed. Brighton Collaboration diagnosis criteria for myocarditis were applied based on patient history, clinical examination, laboratory data, electrocardiograms, echocardiography, magnetic resonance imaging and myocardial biopsy. Poisson regression was used to estimate incidence rate ratios, comparing the register-based outcome variable to validated outcomes. Interrater reliability was assessed by a blinded re-evaluation.

Results: Overall, 95.6% (327/342) of cases registered as myocarditis were confirmed (definite, probable or possible myocarditis according to Brighton Collaboration diagnosis criteria, positive predictive value 0.96 [95% CI 0.93-0.98]). Of the 4.4% (15/342) cases reclassified as no myocarditis or as insufficient information, two cases had been exposed to the COVID-19 vaccine no more than 28 days before the myocarditis diagnosis, two cases were exposed >28 days before admission and 11 cases were unexposed to the vaccine. The reclassification had only minor impact on incidence rate ratios for myocarditis following COVID-19 vaccination. In total, 51 cases were sampled for a blinded re-evaluation. Of the 30 randomly sampled cases initially classified as either definite or probably myocarditis, none were re-classified after re-evaluation. Of the in all 15 cases initially classified as no myocarditis or insufficient information, 7 were after re-evaluation re-classified as probable or possible myocarditis. This re-classification was mostly due to substantial variability in electrocardiogram interpretation.

Conclusion: This validation of register-based diagnoses of myocarditis by manual patient record review confirmed the register diagnosis in 96% of cases and had high interrater reliability. Reclassification had only a minor impact on the incidence rate ratios for myocarditis following COVID-19 vaccination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Upsala journal of medical sciences
Upsala journal of medical sciences 医学-医学:内科
CiteScore
5.60
自引率
0.00%
发文量
31
审稿时长
6-12 weeks
期刊介绍: Upsala Journal of Medical Sciences is published for the Upsala Medical Society. It has been published since 1865 and is one of the oldest medical journals in Sweden. The journal publishes clinical and experimental original works in the medical field. Although focusing on regional issues, the journal always welcomes contributions from outside Sweden. Specially extended issues are published occasionally, dealing with special topics, congress proceedings and academic dissertations.
期刊最新文献
Novel diagnostics for improved treatment of gynecological cancer. Evaluation of drug delivery vehicles for improved transduction of oncolytic adenoviruses in solid tumor tissue. Special issue: frontiers in recent advances on cancer diagnosis and treatment. Determinants of growth differentiation factor 15 plasma levels in outpatients with peripheral arterial disease. From early methods for DNA diagnostics to genomes and epigenomes at high resolution during four decades - a personal perspective.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1